TL;DR
A six-gene-fibrosis-based prognostic model based on six genes stratifies survival risk and correlates with immune features and drug sensitivity, but provides a preliminary framework requiring prospective clinical validation.
Functional enrichment analysis revealed that the prognostic model was markedly linked with the modulation of the immune microenvironment and tumor progression in breast cancer.
It is suggested that glycolytic activity is closely associated with both drug resistance and clinical prognosis in LUAD, and the proposed integrative model holds promise for enhancing precision treatment decision-making through optimized risk assessment and rational selection of chemotherapeutic regimens.
A seven-gene immune-related prognostic signature that, combined with clinicopathological parameters, provides a robust tool for individualized survival prediction and may guide precision management in CRC patients is developed and validated.
A computationally derived and externally validated prognostic model for BRCA based on migrasome and tumor microenvironment features successfully stratifies patients into groups with divergent clinical outcomes, immune profiles, and therapeutic responses, providing insights into BRCA heterogeneity and prognosis.
Findings link KRT expression to clinical outcomes, the tumor microenvironment and therapeutic response in LUAD, suggesting roles for KRTs in cancer progression, chemotherapy resistance and predictive potential for immunotherapy response.
A READ-derived response-associated gene signature for recurrence stratification and exploratory cross-cohort evaluation in additional colorectal cancer cohorts, while further exploring its association with treatment-response phenotypes.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
